Skip to main content
. 2024 Feb 15;12(2):E231–E236. doi: 10.1055/a-2230-7372

Table 1 Patient and stricture characteristics (N=24).

Patient c haracteristics, n (%)
SD, standard deviation; ASA, American Society of Anesthesiologists.
Age, years, mean ±SD 39.4 ± 14.5
Female gender, n (%) 16 (66.7)
Race/ethnicity, n (%)

  • White

 14 (58.3)

  • Non-White

 10 (41.7)
ASA class, n (%)

  • 1/2

 18 (75)

  • 3

 6 (25)
Body mass index, kg/mm 2 , mean (SD) 23.9 (5.4)
Non-active smoker, n (%) 24 (100)
Primary diagnosis, n (%)

  • Crohn’s disease

 18 (75)

  • Ulcerative colitis

 4 (17)

  • Malignancy/adenoma

 1 (4)

  • Familial adenomatous polyposis

 1 (4)
Active medications, n (%)

  • Biologics

  • Adalimumab

 2 (8)

  • Infliximab

 4 (16)

  • Ustekinumab

 7 (29)

  • Vedolizumab

 3 (12.5)

  • Glucocorticoids

  • Budesonide

 2 (8)

  • Prednisone/prednisolone

 2 (8)

  • Antimetabolites

  • 6-mercaptopurine/azathioprine

 3 (12.5)

  • Methotrexate

 1 (4)
Characterization of strictures

  • Type of stricture

  • Anorectal

 17 (71)

  • Anopouch

 7 (29)

  • Severe strictures (non-traversable)

 24 (100%)

  • Stricture length, cm, mean ± SD

 2.4 ± 1.2